Novo Nordisk A/S
NYSE:NVODrug Manufacturers - General
-$0.48 today
- Market cap
- $173.82B
- Beta
- 0.35
- P/E (TTM)
- 10.2
- EPS (TTM)
- $27.45
- Dividend yield
- 4.18%
Volume 16.12M
Average 16.05M
NVO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Novo Nordisk A/SNYSE: NVO
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of DKK 19.13B (cash outflow) fell 58.6% year over year, behind the +8.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 9.7% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.
Context
- Financing cash flow amounted to 9.2% of revenue in FY2025, up 6.2 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -58.6% toward the trailing-twelve-month pace of +8.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
DKK · from the cash flow
- Latest · FY2025
- (28.41B) DKK
- Year-over-year change
- -425.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.41B) | -425.2% |
| FY2024 | 2024-12-31 | 8.74B | +113.8% |
| FY2023 | 2023-12-31 | (63.16B) | -21.9% |
| FY2022 | 2022-12-31 | (51.8B) | -103.2% |
| FY2021 | 2021-12-31 | (25.49B) | — |
Financing Cash Flow vs competitors
How NVO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.3% is the 6th highest of 10, against a peer median of +9.1%.
- Financing cash flow amounts to 7.3% of revenue for NVO, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 24.19B DKK | +8.3% | -18.1% | 7.3% | |
| LTM Sep 2026 | $18.15B USD | +229.4% | -14.5% | 18.3% | |
| LTM Jun 2026 | $12.89B USD | -7.3% | -19.9% | 20.0% | |
| LTM Jun 2026 | €9.13B EUR | +1442.5% | +16.7% | 18.7% | |
| LTM Jun 2026 | $8.4B USD | -53.8% | -11.4% | 13.2% | |
| LTM Jun 2026 | $6.17B USD | +141.8% | -40.5% | 9.3% | |
| LTM Sep 2026 | $5.39B USD | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.13B USD | -65.2% | +39.1% | 10.8% | |
| LTM Jun 2026 | $2.61B USD | +2060.9% | -25.8% | 3.3% | |
| LTM Jun 2026 | £2.53B GBP | -29.6% | — | 7.6% | |
| Peer median (excluding NVO) | — | +9.1% | -13.0% | 10.8% | |
Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 47.76B | 55.53B | 83.68B | 100.99B | 102.43B |
| Depreciation & Amortization | 6.03B | 7.36B | 9.41B | 19.11B | 21.98B |
| Deferred Income Tax | 11.32B | 13.54B | 20.99B | 26.2B | 28.11B |
| Stock-Based Compensation | 1.04B | 1.54B | 2.15B | 2.29B | 0 |
| Change in Working Capital | (8.66B) | (5.54B) | (12.25B) | 2.59B | 3.74B |
| Accounts Receivables | (12.91B) | (10.82B) | (14.21B) | (14.31B) | 0 |
| Inventory | (1.09B) | (4.77B) | (7.42B) | (9.04B) | 0 |
| Accounts Payables | 3.15B | 6.72B | 10.02B | 3.24B | 0 |
| Other Working Capital | 2.19B | 3.34B | (631M) | 22.7B | 3.74B |
| Other Non-Cash Items | (2.49B) | 6.46B | 4.92B | (30.21B) | (37.16B) |
| Operating Cash Flow | 55B | 78.89B | 108.91B | 120.97B | 119.1B |
| Capital Expenditures | (7.39B) | (14.75B) | (38.9B) | (51.31B) | (90.11B) |
| Acquisitions (Net) | (18.28B) | (7.08B) | 0 | (82.16B) | 1B |
| Purchases of Investments | (7.11B) | (9.74B) | (13.29B) | (19.81B) | (723M) |
| Sales of Investments | 1.17B | 6.65B | 8.29B | 24.39B | 10.67B |
| Other Investing Activities | 4M | (2.61B) | (13.09B) | (4.15B) | (29.97B) |
| Investing Cash Flow | (31.61B) | (24.92B) | (43.89B) | (128.9B) | (79.16B) |
| Debt Repayment | 15.47B | (2.41B) | (1.47B) | 73.06B | 24.74B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (19.45B) | (24.09B) | (29.92B) | (20.18B) | (1.39B) |
| Dividends Paid | (21.52B) | (25.3B) | (31.77B) | (44.14B) | (51.76B) |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (25.49B) | (51.8B) | (63.16B) | 8.74B | (28.41B) |
| Effect of Forex Changes | 591M | (238M) | (119M) | 455M | (727M) |
| Net Change in Cash | (1.51B) | 1.93B | 1.74B | 1.26B | 10.81B |
| Free Cash Flow | 47.62B | 64.13B | 70.01B | 69.66B | 28.99B |
Novo Nordisk A/S
NYSE:NVO
Intrinsic Alpha fair value
Locked
Current Price
$39.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.